GADOBUTROL (gadobutrol) by Bayer is magnetic resonance contrast activity [moa]. Approved for gadolinium-based contrast agent [epc]. First approved in 2023.
Drug data last refreshed 19h ago
Magnetic Resonance Contrast Activity
Gadolinium-based Contrast Agent
MR Image Synthesis With Low Gadobutrol Dose and AI
Dotarem vs Gadobutrol Contrast for Breast MRI
Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging
Worked on GADOBUTROL at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.